Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies

In the last few years, the unprecedented results of immune checkpoint inhibitors have led to a paradigm shift in clinical practice for the treatment of several cancer types. However, the vast majority of patients with gastrointestinal cancer do not benefit from immunotherapy. To date, microsatellite...

Descripción completa

Detalles Bibliográficos
Autores principales: Puccini, Alberto, Battaglin, Francesca, Iaia, Maria Laura, Lenz, Heinz-Josef, Salem, Mohamed E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223273/
https://www.ncbi.nlm.nih.gov/pubmed/32393474
http://dx.doi.org/10.1136/jitc-2019-000404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223273/
https://www.ncbi.nlm.nih.gov/pubmed/32393474
http://dx.doi.org/10.1136/jitc-2019-000404

Ejemplares similares